Cybin Receives Australian Approval for EMBRACE, a Multinational Pivotal Study Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder

- EMBRACE, the second study within the CYB003 Phase 3 PARADIGM program, will enroll 330 participants at approximately 60 clinical sites across the United States, Europe and Australia - - Recently cleared to initiate